Arformoterol ; Defination, Mechanism, Indications, Contra indications,Dosage, Side effects, Drug Interaction ,Pregnancy Catagory


Arformoterol is a long-acting β2 adrenoreceptor agonist (LABA) indicated for the treatment of chronic obstructive pulmonary disease(COPD). It is sold as a solution of arformoterol tartrate to be administered twice daily (morning and evening) by nebulization.It is the active (R,R)-(−)-enantiomer of formoterol and was approved by the United States Food and Drug Administration (FDA) on October 6, 2006 for the treatment of COPD.

Mechanism of action

While it is recognized that β2-receptors are the predominant adrenergic receptors in bronchial smooth muscle and β1-receptors are the predominant receptors in the heart, data indicate that there are also β2-receptors in the human heart comprising 10% to 50% of the total beta-adrenergic receptors. The precise function of these receptors has not been established, but they raise the possibility that even highly selective β2-agonists may have cardiac effects. The pharmacologic effects of β2-adrenoceptor agonist drugs, including arformoterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3′,5′-adenosine monophosphate (cyclic AMP). Increased intracellular cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of proinflammatory mediators from cells, especially from mast cells. In vitro tests show that arformoterol is an inhibitor of the release of mast cell mediators, such as histamine and leukotrienes, from the human lung. Arformoterol also inhibits histamine-induced plasma albumin extravasation in anesthetized guinea pigs and inhibits allergen-induced eosinophil influx in dogs with airway hyper-response.


Contra Indications

Allergies to

  • Beta-Adrenergic Agents


Strengths: 15 mcg/2 mL

Chronic Obstructive Pulmonary Disease – Maintenance

  • 15 mcg inhaled by nebulization twice daily (morning and evening).
  • Maximum Daily Dose: 30 mcg

Side Effects

The most common

More common


Drug Interactions

Arformoterol may interact with following drugs,suppliment & may change the efficacy of drugs

Pregnancy Catagory

FDA Pregnancy Category C


This medication falls into category C. In animal studies, pregnant animals were given this medication and had some babies born with problems. No well-controlled studies have been done in humans. Therefore, this medication may be used if the potential benefits to the mother outweigh the potential risks to the unborn child.


It is not known if arformoterol crosses into human milk. Because many medications can cross into human milk and because of the possibility for serious adverse reactions in nursing infants with use of this medication, a choice should be made whether to stop nursing or stop the use of this medication. logo



Please enter your comment!
Please enter your name here